Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy

NCT00966875 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00966875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00966875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2009
Completion date
June 30, 2012
Enrollment
448 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis